Adenosine

Generic Name: Adenosine

Brand Names: Adenocard, Viva-drops Lubricating Eye Drops

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 58-61-7

Unique Ingredient Identifier: K72T3FS567

Background: The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.

Adenosine was granted FDA approval on 30 October 1989.

Indication: Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions: Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)

Clinical Trials

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Phase 2

Completed

Conditions: Atherosclerosis, Coronary
Heart Disease, Ischemic

Interventions: Drug: Gadolinium
Drug: Adenosine

First Posted Date: 2010-11-04

Last Posted Date: 2014-09-26

Lead Sponsor: Northwestern University

Target Recruit Count: 40

Registration Number: NCT01234870

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Blood Markers for Inflammation and Coronary Artery Vasoreactivity Testing in Patients With Chest Pain and Normal Coronary Arteries

Not Applicable

Conditions: Endothelial Dysfunction
Atherosclerosis
Inflammation
Myocardial Ischemia

Interventions: Drug: Acetylcholine
Drug: Adenosine

First Posted Date: 2010-07-15

Last Posted Date: 2011-02-23

Lead Sponsor: St George's Healthcare NHS Trust

Target Recruit Count: 50

Registration Number: NCT01162824

Locations: 🇬🇧
Department of Cardiology, St George's Healthcare NHS Trust, London, England, United Kingdom

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: adenosine
Drug: regadenoson

First Posted Date: 2010-07-13

Last Posted Date: 2017-06-23

Lead Sponsor: St. Louis University

Target Recruit Count: 46

Registration Number: NCT01161121

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States
🇺🇸
St. Louis University, Saint Louis, Missouri, United States

Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty

Phase 3

Completed

Conditions: Coronary Angioplasty

Interventions: Drug: Placebo
Drug: Adenosine

First Posted Date: 2010-06-22

Last Posted Date: 2011-11-08

Lead Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita

Target Recruit Count: 260

Registration Number: NCT01148147

Locations: 🇮🇹
Giuseppe De Luca, Novara, Italy

Adenosine Cardioplegia; Improved Cardioprotection?

Phase 1

Completed

Conditions: Angina Pectoris

Interventions: Drug: Adenosine

First Posted Date: 2010-05-14

Last Posted Date: 2011-09-30

Lead Sponsor: University Hospital of North Norway

Target Recruit Count: 60

Registration Number: NCT01123525

Locations: 🇳🇴
University Hospital of North Norway, Troomsø, Norway

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

Phase 3

Terminated

Conditions: Coronary Artery Disease

Interventions: Drug: Apadenoson SPECT-MPI
Drug: Adenosine SPECT-MPI

First Posted Date: 2009-10-06

Last Posted Date: 2012-05-01

Lead Sponsor: Forest Laboratories

Target Recruit Count: 863

Registration Number: NCT00990327

Locations: 🇺🇸
Forest Investigative Site 235, Akron, Ohio, United States
🇺🇸
Forest Investigative Site 229, Spartanburg, South Carolina, United States
🇺🇸
Forest Investigative Site 227, Chicago, Illinois, United States

and more 119 locations